Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for increasing FSH activity
View Patent ↗The invention provides novel heterodimeric fusion proteins comprising a first polypeptide including an alpha subunit of FSH (αFSH) linked directly or indirectly to a binding partner of neonatal Fc receptor (FcRn) and a second polypeptide including a beta subunit of FSH (βFSH) linked directly or indirectly to an FcRn binding partner. In one embodiment the FcRn binding partner includes an Fc fragment of an immunoglobulin, e.g., an Fc fragment of IgG. Also provided are methods making and using the fusion proteins of the invention. The invention provides a method for increasing fertility in a subject and a method for treating a subject having a disease state responsive to treatment by FSH.
1. A method for increasing FSH activity in a subject in need thereof, the method comprising administering to the subject an effective amount of a heterodimeric fusion protein comprising two associated polypeptide chains, the first chain comprising an alpha subunit of follicle stimulating hormone (α-FSH) conjugated to an FcRn binding partner and the second chain comprising a beta subunit of follicle stimulating hormone (β-FSH) conjugated to an FcRn binding partner, wherein said heterodimeric fusion protein increases FSH activity in said subject.
2. The method of claim 1 , wherein the subject is a human.
3. The method of claim 2 , wherein the human is a female.
4. The method of claim 3 , wherein the increased FSH activity improves fertility in said female.
5. The method of claim 3 , wherein said female is infertile and is undergoing in vitro fertilization.
6. The method of claim 2 , wherein the human is a male.
7. The method of claim 2 , wherein the heterodimeric fusion protein increases gonadal weight in said human.
8. The method of claim 1 , wherein the fusion protein is administered intravenously, intramuscularly, subcutaneously, orally, buccally, sublingually, nasally, rectally, vaginally, via an aerosol, or via a pulmonary route.
9. The method of claim 1 , wherein said first chain or second chain further comprises a linker between the FSH subunit and the FcRn binding partner.
10. The method of claim 9 , wherein said linker comprises 15 amino acids.
11. The method of claim 9 , wherein said linker is selected from the group consisting of (GGS)n and (GGGGS)n, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
12. The method of claim 9 , wherein said linker is selected from the group consisting of GGG, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ′ID NO: 10, and SEQ ID NO: 9.
13. The method of claim 9 , wherein said linker is a non-peptide linker.
14. The method of claim 1 , wherein said FcRn binding partner is an Fc fragment.
15. The method of claim 14 , wherein said Fc fragment is amino acids 145 to 371 of SEQ ID NO: 4.
16. The method of claim 1 , wherein said first chain comprises SEQ ID NO: 2 and said second chain comprises SEQ ID NO: 4.
17. The method of claim 1 , wherein said first chain is encoded by SEQ ID NO: 1 and said second chain is encoded by SEQ ID NO: 3.
18. The method of claim 1 , wherein said fusion protein has the formula:
αFSH-L-Fc:βFSH-L-Fc
wherein αFSH is an alpha subunit of FSH, βFSH is a beta subunit of FSH, L is a linker or direct bond, Fc is an Fc fragment of an immunoglobulin, the colon (:) is an association between the polypeptide chains, wherein the carboxy termini of αFSH and βFSH are linked directly or indirectly through L to the amino terminus of the respective Fc.
19. The method of claim 1 , wherein said fusion protein has the formula:
Fc-L-αFSH:Fc-L-βFSH
wherein αFSH is an alpha subunit of FSH, βFSH is a beta subunit of FSH, L is a linker or direct bond, Fc is an Fc fragment of an immunoglobulin, the colon (:) is an association between the polypeptide chains, wherein the amino termini of αFSH and βFSH are linked directly or indirectly through L to the carboxy terminus of the respective Fc.